.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Teva
Harvard Business School
QuintilesIMS
Merck
Cantor Fitzgerald
Citi
Dow
Colorcon
US Army

Generated: November 19, 2017

DrugPatentWatch Database Preview

Rivastigmine tartrate - Generic Drug Details

« Back to Dashboard

What are the generic sources for rivastigmine tartrate and what is the scope of rivastigmine tartrate freedom to operate?

Rivastigmine tartrate
is the generic ingredient in two branded drugs marketed by Novartis, Watson Labs, Dr Reddys Labs Inc, Sun Pharm Inds Ltd, Cadila Pharms Ltd, Macleods Pharms Ltd, Apotex Inc, Aurobindo Pharma Ltd, Orchid Hlthcare, Alembic Pharms Ltd, and Ajanta Pharma Ltd, and is included in twelve NDAs. Additional information is available in the individual branded drug profile pages.

There are thirty-two drug master file entries for rivastigmine tartrate. Nineteen suppliers are listed for this compound. There is one tentative approval for this compound.

Pharmacology for rivastigmine tartrate

Tentative approvals for RIVASTIGMINE TARTRATE

Applicant Application No. Strength Dosage Form
u► Subscribe2MG/MLSOLUTION; ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cadila Pharms Ltd
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL203844-004Feb 13, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Dr Reddys Labs Inc
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL077130-003Oct 31, 2007ABRXNoNo► Subscribe► Subscribe► Subscribe
Novartis
EXELON
rivastigmine tartrate
CAPSULE;ORAL020823-006Apr 21, 2000ABRXYesYes► Subscribe► Subscribe► Subscribe
Ajanta Pharma Ltd
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL207797-001Sep 28, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Ajanta Pharma Ltd
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL207797-002Sep 28, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Alembic Pharms Ltd
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL091689-004Jun 12, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Cadila Pharms Ltd
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL203844-001Feb 13, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Macleods Pharms Ltd
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL203148-003Aug 22, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
Cadila Pharms Ltd
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL203844-002Feb 13, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Apotex Inc
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL091072-002May 16, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: rivastigmine tartrate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis
EXELON
rivastigmine tartrate
CAPSULE;ORAL020823-006Apr 21, 2000► Subscribe► Subscribe
Novartis
EXELON
rivastigmine tartrate
CAPSULE;ORAL020823-003Apr 21, 2000► Subscribe► Subscribe
Novartis
EXELON
rivastigmine tartrate
CAPSULE;ORAL020823-004Apr 21, 2000► Subscribe► Subscribe
Novartis
EXELON
rivastigmine tartrate
SOLUTION;ORAL021025-001Apr 21, 2000► Subscribe► Subscribe
Novartis
EXELON
rivastigmine tartrate
CAPSULE;ORAL020823-005Apr 21, 2000► Subscribe► Subscribe
Novartis
EXELON
rivastigmine tartrate
CAPSULE;ORAL020823-004Apr 21, 2000► Subscribe► Subscribe
Novartis
EXELON
rivastigmine tartrate
CAPSULE;ORAL020823-006Apr 21, 2000► Subscribe► Subscribe
Novartis
EXELON
rivastigmine tartrate
CAPSULE;ORAL020823-003Apr 21, 2000► Subscribe► Subscribe
Novartis
EXELON
rivastigmine tartrate
CAPSULE;ORAL020823-005Apr 21, 2000► Subscribe► Subscribe
Novartis
EXELON
rivastigmine tartrate
SOLUTION;ORAL021025-001Apr 21, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Teva
McKesson
UBS
Cantor Fitzgerald
Cipla
Julphar
AstraZeneca
QuintilesIMS
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot